Figure 4From: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathwaysMCL-1 down-regulation induces apoptosis in OS cell lines. MCL-1 protein expression (A) and annexin V/PI staining (B) in MG63 and SAOS-2 after MCL-1 silencing with siRNA.Back to article page
